A 62-year-old woman with extensive-stage small cell lung cancer has completed 4 cycles of cisplatin + etoposide with a partial response. She is now in remission and clinically stable. Which agent is the drug of choice for maintenance therapy to prolong overall survival?

Explanation

## Maintenance Immunotherapy in Extensive-Stage SCLC **Key Point:** Atezolizumab (PD-L1 inhibitor) is the only FDA-approved and guideline-recommended maintenance agent for extensive-stage SCLC after chemotherapy response, based on the IMpower133 trial. ### IMpower133 Trial (Landmark Evidence) **Study Design:** - Extensive-stage SCLC patients with response/stable disease after 4 cycles of cisplatin + etoposide - Randomized to: Atezolizumab vs. placebo (maintenance) **Results:** - **Median OS:** 12.3 months (atezolizumab) vs. 10.3 months (placebo) → **2-month OS benefit** - **Median PFS:** 5.2 months vs. 4.3 months - **Grade ≥3 adverse events:** 18% (atezolizumab) vs. 3% (placebo) — manageable with monitoring **High-Yield:** Atezolizumab is the ONLY agent with level 1A evidence for maintenance in extensive-stage SCLC. This is a frequently tested fact. ### Mechanism: Why Immunotherapy Works in SCLC ```mermaid flowchart TD A[SCLC tumor cells]:::outcome --> B[High PD-L1 expression]:::outcome B --> C[Exhausted T cells cannot attack]:::outcome D[Atezolizumab blocks PD-L1]:::action --> E[Restores T-cell immunity]:::action E --> F[Tumor cell apoptosis]:::outcome style A fill:#e8f4f8 style B fill:#e8f4f8 style C fill:#ffe8e8 style D fill:#e8f8e8 style E fill:#e8f8e8 style F fill:#e8f4f8 ``` ### Comparison of Maintenance Options in SCLC | Agent | Class | Evidence in SCLC | Status | |-------|-------|------------------|--------| | **Atezolizumab** | PD-L1 inhibitor | IMpower133 (OS +2 mo) | **FDA approved, guideline standard** | | **Nivolumab** | PD-1 inhibitor | CheckMate 331 (negative) | Not recommended | | **Bevacizumab** | Anti-VEGF | No SCLC data | Not indicated | | **Erlotinib** | EGFR TKI | No benefit in EGFR WT SCLC | Not indicated | **Clinical Pearl:** CheckMate 331 tested nivolumab (PD-1 inhibitor) as maintenance in extensive-stage SCLC and failed to show OS benefit, making atezolizumab (PD-L1 inhibitor) the preferred checkpoint inhibitor. **Warning:** Do not confuse atezolizumab with nivolumab — both are checkpoint inhibitors, but only atezolizumab has proven maintenance benefit in SCLC. Nivolumab failed in CheckMate 331. ### Dosing & Administration - Atezolizumab 1200 mg IV every 3 weeks - Continued until disease progression or unacceptable toxicity - Monitor for immune-related adverse events (irAEs): pneumonitis, hepatitis, colitis **Mnemonic:** **ATEZ** = **A**fter **T**reatment with **E**toposide/**Z**isplatin (maintenance in SCLC) [cite:Harrison 21e Ch 105; IMpower133 Trial, Lancet 2019]